Pathologic response rates of gemcitabine/cisplatin versus methotrexate/vinblastine/adriamycin/cisplatin neoadjuvant chemotherapy for muscle invasive urothelial bladder cancer

Advances in Urology

Volumn , Issue , 2013, Pages

  Lee, Franklin C ^a,b   Harris, William ^a,c   Cheng, Heather H ^a,c   Shenoi, Jaideep ^d   Zhao, Song ^a,c   Wang, Junfeng ^e   Champion, Thomas ^a   Izard, Jason ^a   Gore, John L ^a,c   Porter, Michael ^a   Yu, Evan Y ^a,c   Wright, Jonathan L ^a,c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c USA   (United States)

^d Group Health Permanente   (United States)

^e UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84893667981     PISSN: 16876369     EISSN: 16876377     Source Type: Journal    
DOI: 10.1155/2013/317190     Document Type: Article

References (19)

1. Stein J. P., Lieskovsky G., Cote R., Groshen S., Feng A.-C., Boyd S., Skinner E., Bochner B., Thangathurai D., Mikhail M., Raghavan D., Skinner D. G., Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. Journal of Clinical Oncology 2001 19 3 666 675 2-s2.0-0035254218 (Pubitemid 32120143)
2. Shariat S. F., Karakiewicz P. I., Palapattu G. S., Lotan Y., Rogers C. G., Amiel G. E., Vazina A., Gupta A., Bastian P. J., Sagalowsky A. I., Schoenberg M. P., Lerner S. P., Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. Journal of Urology 2006 176 6, part 1 2414 2422 2-s2.0-33751057732 10.1016/j.juro.2006.08.004 (Pubitemid 44755069)
3. Svatek R. S., Shariat S. F., Novara G., Skinner E. C., Fradet Y., Bastian P. J., Kamat A. M., Kassouf W., Karakiewicz P. I., Fritsche H.-M., Izawa J. I., Tilki D., Ficarra V., Volkmer B. G., Isbarn H., Dinney C. P., Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort. BJU International 2011 107 6 898 904 2-s2.0-79952618440 10.1111/j.1464-410X.2010.09628.x
4. Grossman H. B., Natale R. B., Tangen C. M., Speights V. O., Vogelzang N. J., Trump D. L., DeVere White R. W., Sarosdy M. F., Wood D. P. Jr., Raghavan D., Crawford E. D., Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. New England Journal of Medicine 2003 349 9 859 866 2-s2.0-0041429507 10.1056/NEJMoa022148 (Pubitemid 37025405)
5. Meeks J. J., Bellmunt J., Bochner B. H., Clarke N. W., Daneshmand S., Galsky M. D., Hahn N. M., Lerner S. P., Mason M., Powles T., Sternberg C. N., Sonpavde G., A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. European Urology 2012 62 3 523 533 10.1016/j.eururo.2012.05.048
6. Sternberg C. N., Donat S. M., Bellmunt J., Millikan R. E., Stadler W., De Mulder P., Sherif A., von der Maase H., Tsukamoto T., Soloway M. S., Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. Urology 2007 69 supplement 1 62 79 2-s2.0-33846581566 10.1016/j.urology.2006.11.018
7. Sonpavde G., Sternberg C. N., Neoadjuvant chemotherapy for invasive bladder cancer. Current Urology Reports 2012 13 2 136 146 2-s2.0-84856578637 10.1007/s11934-012-0236-2
8. Raghavan D., Shipley W. U., Garnick M. B., Russell P. J., Richie J. P., Biology and management of bladder cancer. New England Journal of Medicine 1990 322 16 1129 1138 2-s2.0-0025321388 (Pubitemid 20149531)
9. Rosenblatt R., Sherif A., Rintala E., Wahlqvist R., Ullén A., Nilsson S., Malmström P.-U., Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer. European Urology 2012 61 6 1229 1238 2-s2.0-84860311115 10.1016/j.eururo.2011.12.010
10. Splinter T. A. W., Scher H. I., Denis L., Bukowski R., Simon S., Klimberg I., Soloway M., Vogelzang N. J., Van Tinteren H., Herr H., The prognostic value of the pathological response to combination chemotherapy before cystectomy in patients with invasive bladder cancer. Journal of Urology 1992 147 3 606 608 2-s2.0-0026561214
11. Von Der Maase H., Sengelov L., Roberts J. T., Ricci S., Dogliotti L., Oliver T., Moore M. J., Zimmermann A., Arning M., Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. Journal of Clinical Oncology 2005 23 21 4602 4608 2-s2.0-23044501890 10.1200/JCO.2005.07.757 (Pubitemid 46224062)
12. Von der Maase H., Hansen S. W., Roberts J. T., Dogliotti L., Oliver T., Moore M. J., Bodrogi I., Albers P., Knuth A., Lippert C. M., Kerbrat P., Sanchez Rovira P., Wersall P., Cleall S. P., Roychowdhury D. F., Tomlin I., Visseren-Grul C. M., Conte P. F., Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. Journal of Clinical Oncology 2000 18 17 3068 3077 2-s2.0-0033857218
13. David K. A., Milowsky M. I., Ritchey J., Carroll P. R., Nanus D. M., Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the national cancer data base. Journal of Urology 2007 178 2 451 454 2-s2.0-34447095141 10.1016/j.juro.2007.03.101 (Pubitemid 47030482)
14. Griffiths G., Hall R., Sylvester R., Raghavan D., Parmar M. K., International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. Journal of Clinical Oncology 2011 29 16 2171 2177 2-s2.0-79957960529 10.1200/JCO.2010.32.3139
15. Yeshchina O., Badalato G. M., Wosnitzer M. S., Hruby G., Roychoudhury A., Benson M. C., Petrylak D. P., McKiernan J. M., Relative efficacy of perioperative gemcitabine and cisplatin versus methotrexate, vinblastine, adriamycin, and cisplatin in the management of locally advanced urothelial carcinoma of the bladder. Urology 2012 79 2 384 390 2-s2.0-84856749663 10.1016/j.urology.2011.10.050
16. Fairey A., Danesmand S., Quinn D., Dorff T., Dorin R., Lieskovsky G., Schuckman A., Cai J., Miranda G., Skinner E. C., Neoadjuvant chemotherapy with gemcitabine/cisplatin vs methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive urothelial carcinoma of the bladder: a retrospective analysis from the University of Southern California. Urologic Oncology 2013 31 8 1737 1743 10.1016/j.urolonc.2012.07.005
17. Dash A., Pettus J. A. IV, Herr H. W., Bochner B. H., Dalbagni G., Donat S. M., Russo P., Boyle M. G., Milowsky M. I., Bajorin D. F., A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Cancer 2008 113 9 2471 2477 2-s2.0-55549148741 10.1002/cncr.23848
18. Pal S. K., Ruel N. H., Wilson T. G., Yuh B. E., Retrospective analysis of clinical outcomes with neoadjuvant cisplatin-based regimens for muscle invasive bladder cancer. Clinical Genitourinary Cancer 2012 10 4 246 250 10.1016/j.clgc.2012.08.004
19. Weight C. J., Garcia J. A., Hansel D. E., Fergany A. F., Campbell S. C., Gong M. C., Jones J. S., Klein E. A., Dreicer R., Stephenson A. J., Lack of pathologic down-staging with neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder. Cancer 2009 115 4 792 799 2-s2.0-60849134836 10.1002/cncr.24106